Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Orlistat Clear all
Terminated Not applicable Interventional Results available

Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia

NCT00794963
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan, As selected by community physician
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
19 Years to 79 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 2, 2026, 10:13 PM EDT
Active, not recruiting No phase listed Observational

Weight Loss Management in Endometrial Cancer Survivors

NCT06877572
View directory record Official record
Conditions
Endometrial Cancer Survivors, Weight Management, Early Stage Endometrial Cancer
Interventions
Weight loss with pharmacotherapy, Weight loss without pharmacotherapy
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 2, 2026, 10:13 PM EDT
Completed Phase 4 Interventional Results available

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

NCT05579249
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 2, 2026, 10:13 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases

NCT00001723
View directory record Official record
Conditions
Diabetes Mellitus, Hypertension, Metabolic Disease, Obesity, Sleep Apnea Syndrome
Interventions
Orlistat, Placebo
Drug
Lead sponsor
Jack Yanovski
NIH
Eligibility
12 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Sep 2, 2026, 10:13 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia

NCT01675154
View directory record Official record
Conditions
Type 1 Hyperlipoproteinemia
Interventions
SLx-4090 placebo, Orlistat Placebo, Orlistat, Slx-4090
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Sep 2, 2026, 10:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Fat Perception in Humans (09-0873)

NCT01128400
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 2, 2026, 10:13 PM EDT
Completed Phase 4 Interventional

Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus

NCT00207311
View directory record Official record
Conditions
Fatty Liver, Hepatitis C
Interventions
Xenical, Pegasys, Copegus, Xenicare Program
Drug · Behavioral
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Sep 2, 2026, 10:13 PM EDT
Terminated Phase 2 Interventional Results available

Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity

NCT01351753
View directory record Official record
Conditions
Obesity, Metabolic Syndrome X
Interventions
Metformin, Orlistat, Topiramate, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
40 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 2, 2026, 10:13 PM EDT
Completed Not applicable Interventional Results available

Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder

NCT00601354
View directory record Official record
Conditions
Overweight, Eating Disorders
Interventions
Emotion regulation group therapy, Orlistat/alli program
Behavioral · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2013 · Synced Sep 2, 2026, 10:13 PM EDT
Terminated Phase 4 Interventional

Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding

NCT01597531
View directory record Official record
Conditions
Type 2 Diabetes, Gastric Banding
Interventions
Liraglutide, Orlistat, Liraglutide + Orlistat
Drug
Lead sponsor
East Carolina University
Other
Eligibility
25 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced Sep 2, 2026, 10:13 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effectiveness of Brief Counseling for Weight Management

NCT00212199
View directory record Official record
Conditions
1. Obesity
Interventions
orlistat, Brief cognitive behavioral counseling
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
25 Years to 55 Years
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2010 · Synced Sep 2, 2026, 10:13 PM EDT
Completed Phase 2 Interventional

Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects

NCT01126970
View directory record Official record
Conditions
Obesity
Interventions
Velneperit 400 mg, Orlistat 120 mg, Orlistat Placebo, Velneperit Placebo, Reduced Calorie Diet
Drug · Other
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 65 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Santa Rosa, California • Waterbury, Connecticut • Clearwater, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Sep 2, 2026, 10:13 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Orlistat in Body Composition

NCT00752726
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Orlistat, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Baton Rouge, Louisiana • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Sep 2, 2026, 10:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment of Obesity and Binge Eating: Behavioral Weight Loss Versus Stepped Care

NCT00829283
View directory record Official record
Conditions
Obesity, Binge Eating
Interventions
Behavioral Weight Loss, Behavioral Weight Loss + Guided self-help Cognitive-behavioral Therapy, Placebo, Sibutramine/Orlistat
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 2, 2026, 10:13 PM EDT
Completed Phase 3 Interventional Results available

Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained Infertility

NCT02432209
View directory record Official record
Conditions
Infertility, Female
Interventions
Caloric Restriction, Orlistat, Moderate physical activity
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
10
States / cities
San Francisco, California • Augusta, Georgia • Southfield, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Sep 2, 2026, 10:13 PM EDT
Recruiting Phase 2 Interventional

Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia

NCT05816343
View directory record Official record
Conditions
Type 1 Hyperlipoprotenemia
Interventions
Orlistat, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
8 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 2, 2026, 10:13 PM EDT
Completed Phase 2 Interventional Results available

Orlistat for the Treatment of Type I Hyperlipoproteinemia

NCT02767531
View directory record Official record
Conditions
Hyperlipoproteinemia Type I, Hypertriglyceridemia
Interventions
Orlistat
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
8 Years to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 2, 2026, 10:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss

NCT00108524
View directory record Official record
Conditions
Diabetes Mellitus, Obesity
Interventions
Low carbohydrate ketogenic diet, Orlistat, Low-fat diet
Behavioral · Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 69 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Sep 2, 2026, 10:13 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Effect of Modified Sham Feeding With Orlistat in Overweight and Obese Subjects

NCT01719419
View directory record Official record
Conditions
Overweight
Interventions
Placebo, Orlistat
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Sep 2, 2026, 10:13 PM EDT
Completed Phase 4 Interventional

Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)

NCT00160407
View directory record Official record
Conditions
Fatty Liver, Hepatitis
Interventions
Orlistat (Xenical), 1400 kcal diet (30% fat)
Drug · Behavioral
Lead sponsor
St. Louis University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
St Louis, Missouri • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2007 · Synced Sep 2, 2026, 10:13 PM EDT
Active, not recruiting No phase listed Observational

Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

NCT07188545
View directory record Official record
Conditions
Cardiovascular Kidney Metabolic Syndrome
Interventions
Intervention, Active Comparator
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
23,280,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 2, 2026, 10:13 PM EDT
Terminated Phase 4 Interventional Results available

LOSS- Louisiana Obese Subjects Study

NCT00115063
View directory record Official record
Conditions
Obesity
Interventions
group sessions, sibutramine, orlistat, diethylpropion, Low Calorie Diet, Health One, Intensive Medical Combination Therapy for Obesity, Control Condition
Behavioral · Drug · Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 60 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Sep 2, 2026, 10:13 PM EDT
Terminated Phase 4 Interventional Results available

EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

NCT04531176
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Weight Management Program (WMP), Traditional care, Phentermine / Topiramate Extended Release Oral Capsule, naltrexone/bupropion extended-release, liraglutide 3.0 mg, Orlistat
Other · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 2, 2026, 10:13 PM EDT
Terminated Not applicable Interventional Results available

Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients

NCT00871845
View directory record Official record
Conditions
Obesity, Insulin Resistance, Metabolic Syndrome, Hepatitis C
Interventions
Dietary and Lifestyle modification educational sessions
Behavioral
Lead sponsor
Hossam Kandil
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Sep 2, 2026, 10:13 PM EDT